Combination therapy for treatment of hbv infections

Abstract

Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2 a, or another interferon analog. The combination therapy is useful for the treatment of HBV infection. Also provided herein are compositions comprising a compound of Formula I and peginterferon alfa-2 a, or another interferon analog.

1 . A method of treating an HBV infection in a subject in need thereof, comprising administering to the subject a capsid assembly inhibitor and an interferon. 
     
     
         2 . The method of  claim 1 , wherein the interferon is selected from the group consisting of interferon alpha, interferon alpha-2a, recombinant interferon alpha-2a, peginterferon-alpha 2a, interferon alpha-2b, recombinant interferon alpha-2b, interferon alpha-2b XL, peginterferon alpha-2b, glycosylated interferon alpha-2b, interferon alpha-2c, recombinant interferon alpha-2c, interferon beta, interferon beta-la, peginterferon beta-1a, interferon delta, interferon lambda, peginterferon lambda-1, interferon omega, interferon tau, gamma interferon, interferon alfacon-1, interferon alpha-n1, interferon alpha-n3,albinterferon alpha-2b, BLX-883, DA-3021, PEG-Infergen, and BELEROFON. 
     
     
         3 . The method of  claim 2 , wherein the interferon is selected from the group consisting of peginterferon alpha-2a, peginterferon alpha-2b, glycosylated interferon alpha-2b, peginterferon beta-1a, and peginterferon lambda-1. 
     
     
         4 . The method of  claim 3 , wherein the interferon is peginterferon alpha-2a. 
     
     
         5 . The method of  claim 1 , wherein the capsid assembly inhibitor is a compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof; 
         wherein 
         R 4  is H or C 1 -C 6  alkyl; 
         wherein each R 5  is independently selected at each occurrence from the group consisting of CH 3 , C 1 -C 6  alkoxy, halo, —CN, —NO 2 , —(L) m —SR 9 , —(L) m —S(═O)R 9 , —(L) m —S(═O) 2 R 9 , —(L) m —NHS(═O) 2 R 9 , —(L) m —C(═O)R 9 , —(L) m —OC(═O)R 9 , —(L) m CO 2 R 8 , —(L) m —OCO 2 R 8 , —(L) m —N(R 8 ) 2 , —(L)—C(═O)N(R 8 ) 2 , —(L) m —OC(═O)N(R 8 ) 2 , —(L)—NHC(═O)NH(R 8 ), —(L) m —NHC(═O)R 9 , —(L) m —NHC(═O) OR 9 , —(L) m —C(OH)(R 8 ) 2 , —(L) m C(NF1 2 )(R 8 ) 2 , —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl and —C 1 -C 6  trihaloalkyl; 
         L is independently, at each occurrence, a bivalent radical selected from —(C 1 -C 3  alkylene)-, —(C 3 -C 7  cycloalkylene)-, —(C 1 -C 3  alkylene) m —O—(C 1 -C 3  alkylene) m —, or —(C 1 -C 3  alkylene) m —NH—(C 1 -C 3  alkylene) m —; 
         each R 8  is independently, at each occurrence, H, C 1 -C 6  alkyl, —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl, —C 1 -C 6  trihaloalkyl, C 1 -C 6  heteroalkyl, C 3 -C 10  cycloalkyl, C 3 -C 10  heterocycloalkyl, aryl, heteroaryl, —C 1 -C 4  alkyl-(C 3 -C 10  cycloalkyl), —C 1 -C 4  alkyl-(C 3 -C 10  heterocycloalkyl), —C 1 -C 4  alkyl-(aryl), or —C 1 -C 4  alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with 1-5 substituents selected from R 2 ; 
         R 9  is C 1 -C 6  alkyl, —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl, —C 1 -C 6  trihaloalkyl, C 1 -C 6  heteroalkyl, C 3 -C 10  cycloalkyl, a C 3 -C 10  heterocycloalkyl, aryl, heteroaryl, —C 1 -C 4  alkyl-(C 3 -C 10  cycloalkyl), —C 1 -C 4  alkyl-(C 3 -C 10  heterocycloalkyl), —C 1 -C 4  alkyl-(aryl), or —C 1 -C 4  alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 0-5 substituents selected from R 2 ; 
         R 10  is OH, C 1 -C 6  alkyl, C 1 -C 6  alkyl-OH, —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl, —C 1 -C 6  trihaloalkyl, C 1 -C 6  heteroalkyl, C 3 -C 10  cycloalkyl, a C 3 -C 10  heterocycloalkyl, aryl, heteroaryl, —C 1 -C 4  alkyl-(C 3 -C 10  cycloalkyl), —C 1 -C 4  alkyl-(C 3 -C 10  heterocycloalkyl), —C 1 -C 4  alkyl-(aryl), or —C 1 -C 4  alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R 2 ; 
         R 11  is a bond or C 1 -C 3  alkylene, wherein the C 1 -C 3  alkylene is optionally substituted with 1-3 substituents selected from R 2 ; 
         R 2  is independently selected at each occurrence from the group consisting of OH, halo, —CN, —NO 2 , —C 1 -C 6  alkyl, —C 1 -C 6  alkoxy, —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl, —C 1 -C 6  trihaloalkyl, —C 1 -C 6  heteroalkyl, and C(O)—C 1 -C 6  alkyl; 
         w is 0, 1 or 2; 
         each occurrence of x is independently selected from the group consisting of 0, 1, 2, 3 and 4; 
         each occurrence of y is independently selected from the group consisting of 1, 2, and 3; 
         each occurrence of z is independently selected from the group consisting of 0, 1, 2, and 3; 
         each occurrence of m is independently 0, 1 or 2. 
       
     
     
         6 . A method of treating an HBV infection in a subject in need thereof, comprising administering to the subject peginterferon alfa-2a and a compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof; 
         wherein 
         R 4  is H or C 1 -C 6  alkyl;
 wherein each R 5  is independently selected at each occurrence from the group consisting of CH 3 , C 1 -C 6  alkoxy, halo, —CN, —NO 2 , —(L) m —SR 9 , —(L) m —S(═O)R 9 , —(L) m —S(═O) 2 R 9 , —(L) m —NHS(═O) 2 R 9 , —(L) m —C(═O)R 9 , —(L) m —OC(═O)R 9 , —(L) m CO 2 R 8 , —(L) m —OCO 2 R 8 , —(L) m —N(R 8 ) 2 , 
 (L) m —C(═O)N(R 8 ) 2 , —(L) m —OC(═O)N(R 8 ) 2 , —(L) m —NHC(═O)NH(R 8 ), —(L) m —NHC(═O)R 9 , —(L) m —NHC (═O)OR 9 , —(L) m —C(OH)(R 8 ) 2 , —(L) m C(NH 2 )(R 8 ) 2 , —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl and —C 1 -C 6  trihaloalkyl; 
 L is independently, at each occurrence, a bivalent radical selected from —(C 1 -C 3  alkylene)-, —(C 3 -C 7  cyclo alkylene)-, —(C 1 -C 3  alkylene) m —O—(C 1 -C 3  alkylene) m -, or —(C 1 -C 3  alkylene) m —NH—(C 1 -C 3  alkylene) m -; 
 
         each R 8  is independently, at each occurrence, H, C 1 -C 6  alkyl, —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl, —C 1 -C 6  trihaloalkyl, C 1 -C 6  heteroalkyl, C 3 -C 10  cycloalkyl, C 3 -C 10  heterocycloalkyl, aryl, heteroaryl, —C 1 -C 4  alkyl-(C 3 -C 10  cycloalkyl), —C 1 -C 4  alkyl-(C 3 -C 10  heterocycloalkyl), —C 1 -C 4  alkyl-(aryl), or —C 1 -C 4  alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with 1-5 substituents selected from R 2 ; 
         R 9  is C 1 -C 6  alkyl, —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl, —C 1 -C 6  trihaloalkyl, C 1 -C 6  heteroalkyl, C 3 -C 10  cycloalkyl, a C 3 -C 10  heterocycloalkyl, aryl, heteroaryl, —C 1 -C 4  alkyl-(C 3 -C 10  cycloalkyl), —C 1 -C 4  alkyl-(C 3 -C 10  heterocycloalkyl), —C 1 -C 4  alkyl-(aryl), or —C 1 -C 4  alkyl- (heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 0-5 substituents selected from R 2 ; 
         R 1 ° is OH, C 1 -C 6  alkyl, C 1 -C 6  alkyl-OH, —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl, —C 1 -C 6  trihaloalkyl, C 1 -C 6  heteroalkyl, C 3 -C 10  cycloalkyl, a C 3 -C 10  heterocycloalkyl, aryl, heteroaryl, —C 1 -C 4  alkyl-(C 3 -C 10  cycloalkyl), —C 1 -C 4  alkyl-(C 3 -C 10  heterocycloalkyl), —C 1 -C 4  alkyl-(aryl), or —C 1 -C 4  alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R 2 ; 
         R 11  is a bond or C l -C 3  alkylene, wherein the C l -C 3  alkylene is optionally substituted with 1-3 substituents selected from R 2 ; 
         R 2  is independently selected at each occurrence from the group consisting of OH, halo, —CN, —NO 2 , —C 1 -C 6  alkyl, —C 1 -C 6  alkoxy, —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl, —C 1 -C 6  trihaloalkyl, —C 1 -C 6  heteroalkyl, and C(O)—C 1 -C 6  alkyl; 
         w is 0, 1 or 2; 
         each occurrence of x is independently selected from the group consisting of 0, 1, 2, 3 and 4; 
         each occurrence of y is independently selected from the group consisting of 1, 2, and 3; 
         each occurrence of z is independently selected from the group consisting of 0, 1, 2, and 3; 
         each occurrence of m is independently 0, 1 or 2. 
       
     
     
         7 . The method of  claim 6 , wherein the peginterferon alfa-2a and compound of Formula I are in a single formulation or unit dosage form. 
     
     
         8 . The method of  claim 7 , further comprising a pharmaceutically acceptable carrier. 
     
     
         9 . The method of  claim 6 , wherein the peginterferon alfa-2a and compound of Formula I are administered separately. 
     
     
         10 . The method of  claim 6 , wherein the subject is human. 
     
     
         11 . The method of  claim 6 , wherein the treatment comprises administering the peginterferon alfa-2a and compound of Formula I at substantially the same time. 
     
     
         12 . The method of  claim 6 , wherein the treatment comprises administering the peginterferon alfa-2a and compound of Formula I at different times. 
     
     
         13 . The method of  claim 12 , wherein the peginterferon alfa-2a is administered to the subject, followed by administration of a compound of Formula I. 
     
     
         14 . The method of  claim 12 , wherein the compound of Formula I is administered to the subject, followed by administration of the peginterferon alfa-2a. 
     
     
         15 . The method of any one of  claim 12 , wherein the peginterferon alfa-2a and compound of Formula I are in separate formulations or unit dosage forms. 
     
     
         16 . The method of  claim 6 , wherein the peginterferon alfa-2a and compound of Formula I are administered at dosages that would not be effective when one or both of the peginterferon alfa-2a and compound of Formula I are administered alone, but which amounts are effective in combination. 
     
     
         17 . A composition comprising peginterferon alfa-2a and a compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof; 
         wherein 
         R 4  is H or C 1 -C 6  alkyl;
 wherein each R 5  is independently selected at each occurrence from the group consisting of CH 3 , C 1 -C 6  alkoxy, halo, —CN, —NO 2 , —(L) m —SR 9 , —(L) m —S(═O)R 9 , —(L) m —S(═O) 2 R 9 , —(L) m —NHS(═O) 2 R 9 , —(L) m —C(═O)R 9 , —(L) m —OC(═O)R 9 , —(L) m CO 2 R 8 , —(L) m —OCO 2 R 8 , —(L) m —N(R 8 ) 2 , —(L) m —C(═O)N(R 8 ) 2 , —(L) m —OC(═O)N(R 8 ) 2 , —(L) m —NHC(═O)NH(R 8 ), —(L) m —NHC(═O)R 9 , —(L) m —NHC (═O)OR 9 , —(L) m —C(OH)(R 8 ) 2 , —(L) m C(NH 2 )(R 8 ) 2 , —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl and —C 1 -C 6  trihaloalkyl; 
 L is independently, at each occurrence, a bivalent radical selected from —(C 1 -C 3  alkylene)-, —(C 3 -C 7  cyclo alkylene)-, —(C 1 -C 3  alkylene) m —O—(C 1 -C 3  alkylene) m — or —(C 1 -C 3  alkylene) m —NH—(C 1 -C 3  alkylene) m -; 
 each R 8  is independently, at each occurrence, H, C 1 -C 6  alkyl, —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl, —C 1 -C 6  trihaloalkyl, C 1 -C 6  heteroalkyl, C 3 -C 10  cycloalkyl, C 3 -C 10  heterocycloalkyl, aryl, heteroaryl, —C 1 -C 4  alkyl-(C 3 -C 10  cycloalkyl), —C 1 -C 4  alkyl-(C 3 -C 10  heterocycloalkyl), —C 1 -C 4  alkyl-(aryl), or —C 1 -C 4  alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with 1-5 substituents selected from R 2 ; 
 R 9  is C 1 -C 6  alkyl, —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl, —C 1 -C 6  trihaloalkyl, C 1 -C 6  heteroalkyl, C 3 -C 10  cycloalkyl, a C 3 -C 10  heterocycloalkyl, aryl, heteroaryl, —C 1 -C 4  alkyl-(C 3 -C 10  cycloalkyl), —C 1 -C 4  alkyl-(C 3 -C 10  heterocycloalkyl), —C 1 -C 4  alkyl-(aryl), or —C 1 -C 4  alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 0-5 substituents selected from R 2 ; 
 R 10  is OH, C 1 -C 6  alkyl, C 1 -C 6  alkyl-OH, —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl, —C 1 -C 6  trihaloalkyl, C 1 -C 6  heteroalkyl, C 3 -C 10  cycloalkyl, a C 3 -C 10  heterocycloalkyl, aryl, heteroaryl, —C 1 -C 4  alkyl-(C 3 -C 10  cycloalkyl), —C 1 -C 4  alkyl-(C 3 -C 10  heterocycloalkyl), —C 1 -C 4  alkyl-(aryl), or —C 1 -C 4  alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R 2 ; 
 R 11  is a bond or C 1 -C 3  alkylene, wherein the C 1 -C 3  alkylene is optionally substituted with 1-3 substituents selected from R 2 ; 
 R 2  is independently selected at each occurrence from the group consisting of OH, halo, —CN, —NO 2 , —C 1 -C 6  alkyl, —C 1 -C 6  alkoxy, —C 1 -C 6  haloalkyl, —C 1 -C 6  dihaloalkyl, —C 1 -C 6  trihaloalkyl, —C 1 -C 6  heteroalkyl, and C(O)—C 1 -C 6  alkyl; 
 w is 0, 1 or 2; 
 each occurrence of x is independently selected from the group consisting of 0, 1, 2, 3 and 4; 
 each occurrence of y is independently selected from the group consisting of 1, 2, and 3; 
 each occurrence of z is independently selected from the group consisting of 0, 1, 2, and 3; 
 
         each occurrence of m is independently 0, 1 or 2. 
       
     
     
         18 . A method of treating an HBV infection in a subject in need thereof comprising administering to the subject an effective amount of the composition of  claim 17 .